ArticleScientific reports2025
Compositional analysis of coffee containing javamide I/II and investigation of health effects in rats fed a high fat diet.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Coffee containing javamide I/II (CCJ12) is commonly found in the market. However, no information is available about chemical composition of CCJ12 and in vivo effects on obesity. Therefore, in this paper, the composition of CCJ12 was analyzed by HPLC and LC/MS, and effects on bodyweight, metabolic (HDL, LDL, TG, leptin, adiponectin), cardiovascular risk (sE-selectin, C-reactive protein,), and inflammatory (MCP-1, TNF-alpha) factors were investigated in a rodent model. In CCJ12, > 700 compounds were identified by LC/MS and the amounts of javamide I/II, caffeine and chlorogenic acids were quantified by HPLC. For the animal study, rats were placed into three groups (each n = 10); (CG group (a control diet with water), FG group (a high fat diet with water), and FCG group (a high fat diet with CCJ12)) and the study was conducted for 20 weeks. The data showed no significant differences in water/food intakes between all three groups. However, the FG and FCG groups showed weight gain, in comparison to the CG group (P < 0.05). Also, the FG and FCG groups showed higher levels of LDL, TG, and leptin than the CG group (P < 0.05). However, no significant differences were found in bodyweight, HDL, LDL, TG, leptin, and adiponectin levels between the FG and FCG groups. Also, no significant differences were noted in sE-selectin, C-reactive protein, and MCP-1 levels between the FG and FCG groups. However, TNF-alpha level was found to be down in the FCG group, in comparison to the FG group (P < 0.05). Our study suggests that CCJ12 may have no adverse effects on bodyweight, HDL, LDL, TG, adiponectin, leptin, sE-selectin, C-reactive protein, and MCP-1, but may have a beneficial effect on TNF-alpha in rats fed a high fat diet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.